中国实用神经疾病杂志
中國實用神經疾病雜誌
중국실용신경질병잡지
CHINESE JOURNAL OF PRACTICAL NERVOUS DISEASES
2015年
13期
7-9
,共3页
躯体化障碍%度洛西汀%利培酮%心理疗法
軀體化障礙%度洛西汀%利培酮%心理療法
구체화장애%도락서정%리배동%심리요법
Somatization disorders%Duloxetine%Risperi-done%Psychotherapy
目的：探讨单用度洛西汀、度洛西汀联合心理疗法、度洛西汀联合利培酮三种治疗方式对躯体化障碍的疗效及其安全性。方法将96例躯体化障碍患者随机分为3组，分别采用度洛西汀、度洛西汀联合心理疗法、度洛西汀联合小剂量利培酮三种治疗方式，疗程均为8周。于治疗前及治疗后第2、4、6、8周末采用17项汉密尔顿抑郁量表（HAMD17）、汉密尔顿焦虑量表（HAMA）及副反应量表（TESS）评定疗效及不良反应。结果（1）治疗后3组HAMD17、HAMA评分均较治疗前减少。（2）8周末三种治疗方式的有效率分别为67.7％、81.8％、93.8％，3组差异有统计学意义（χ2＝7.002，P＝0.030）。（3）联合用药组较单一药物组见效快，差异有统计学意义（P＜0.01）。（4）3组不良反应的发生率差异无统计学有意义（P＞0.05）。结论三种治疗方式对躯体化障碍均有明显疗效；度洛西汀联合利培酮治疗躯体化障碍较单用度洛西汀疗效好，起效快，且不增加不良反应。
目的：探討單用度洛西汀、度洛西汀聯閤心理療法、度洛西汀聯閤利培酮三種治療方式對軀體化障礙的療效及其安全性。方法將96例軀體化障礙患者隨機分為3組，分彆採用度洛西汀、度洛西汀聯閤心理療法、度洛西汀聯閤小劑量利培酮三種治療方式，療程均為8週。于治療前及治療後第2、4、6、8週末採用17項漢密爾頓抑鬱量錶（HAMD17）、漢密爾頓焦慮量錶（HAMA）及副反應量錶（TESS）評定療效及不良反應。結果（1）治療後3組HAMD17、HAMA評分均較治療前減少。（2）8週末三種治療方式的有效率分彆為67.7％、81.8％、93.8％，3組差異有統計學意義（χ2＝7.002，P＝0.030）。（3）聯閤用藥組較單一藥物組見效快，差異有統計學意義（P＜0.01）。（4）3組不良反應的髮生率差異無統計學有意義（P＞0.05）。結論三種治療方式對軀體化障礙均有明顯療效；度洛西汀聯閤利培酮治療軀體化障礙較單用度洛西汀療效好，起效快，且不增加不良反應。
목적：탐토단용도락서정、도락서정연합심리요법、도락서정연합리배동삼충치료방식대구체화장애적료효급기안전성。방법장96례구체화장애환자수궤분위3조，분별채용도락서정、도락서정연합심리요법、도락서정연합소제량리배동삼충치료방식，료정균위8주。우치료전급치료후제2、4、6、8주말채용17항한밀이돈억욱량표（HAMD17）、한밀이돈초필량표（HAMA）급부반응량표（TESS）평정료효급불량반응。결과（1）치료후3조HAMD17、HAMA평분균교치료전감소。（2）8주말삼충치료방식적유효솔분별위67.7％、81.8％、93.8％，3조차이유통계학의의（χ2＝7.002，P＝0.030）。（3）연합용약조교단일약물조견효쾌，차이유통계학의의（P＜0.01）。（4）3조불량반응적발생솔차이무통계학유의의（P＞0.05）。결론삼충치료방식대구체화장애균유명현료효；도락서정연합리배동치료구체화장애교단용도락서정료효호，기효쾌，차불증가불량반응。
Objective To explore the efficacy and safety of duloxetine monotherapy ,combination therapy of duloxetine and risperidone and combination of psychotherapy and duloxetine in the treatment of somatization disorders.Methods A total of 96 patients with somatization disorders were randomly divided into three groups:duloxetine monotherapy ;combination therapy of psychotherapy and duloxetine ,combination therapy of duloxetine and a small dose of risperidone ,for a 8‐week course. The clinical efficacy and safety were evaluated by HAMD17 ,HAMA and TESS before and after 2‐,4‐,6‐ and 8‐week thera‐py.Results ①The scores of HAMD17 and HAMA in all the three group after the treatment were lower than that before treat‐ment. ②At the end of 8th week ,effective rate of the three group were 67.7% 、81.80% and 93.8% ,which had a significant difference(χ2 =7.002 ,P=0.030). ③ The combination group had faster efficacy than the monotherapy group(P< 0.01). ④The rate of adverse events between the three groups showed no statistical difference(P>0.05).Conclusion The three methods all have an effect on patients with somatization disorders ;combination therapy of duloxetine and risperidone performs better and faster effect than duloxetine monotherapy with no increase in adverse events .
